What We Do
Transformative Therapies for Autoimmune Disease
Translating the biology of regulatory T cells into transformational medicines for patients.
The Abata Approach
A New Era: Treg Cell Therapy
Our targeted, autologous Treg cell therapies for progressive multiple sclerosis and other serious autoimmune diseases stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in affected tissues.
Press Release
Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes
ABA-201 aims to benefit patients with type 1 diabetes who have remaining beta cell function.
ABA-201 is currently in IND-enabling studies and on track to enter the clinic in 2025.
Strategic partnership with ElevateBio expanded to support process development and manufacturing work for ABA-201.